Penile cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Van Poppel, H ^a   Watkin, N A ^b   Osanto, S ^c   Moonen, L ^d   Horwich, A ^e   Kataja, V ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INGUINAL LYMPH NODE; JAPANESE; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PENIS CANCER; PERIOPERATIVE PERIOD; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

CHEMORADIOTHERAPY; CIRCUMCISION, MALE; EUROPE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RISK ASSESSMENT;

EID: 84885355422     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt286     Document Type: Article

References (60)

1. Pizzocaro G, Algaba F, Horenblas S et al. EAU Penile cancer guidelines 2009. Eur Urol 2010; 57: 1002-1012.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127: 2893-2917.
3. Lont AP, Horenblas S, Tanis PJ, et al. Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol 2003; 170: 783-786.
4. Leijte JA, Hughes B, Graafland NM, et al. Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol 2009; 27: 3325-3329.
5. Sadeghi R, Gholami H, Zakavi SR, et al. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol 2012; 187: 25-31.
6. Graafland NM, Leijte JA, Olmos RA, et al. Repeat dynamic sentinel node biopsy in locally recurrent penile carcinoma. BJU Int 2010; 105: 1121-1124.
7. Ornellas AA, Seixas AL, Marota A, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994; 151: 1244-1249.
8. Schlenker B, Scher B, Tiling R, et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18f-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol 2012; 30: 55-59.
9. Sobin L, Gospodariwics M, Wittekind C. TNM Classification of Malignant Tumors. UICC International Union Against Cancer, 7th edition. West Sussex, UK: Willy- Blackwell 2009; 239-242.
10. Solsona E, Algaba F, Horenblas S, et al. EAU Guidelines on penile cancer. Eur Urol 2004; 46: 1-8. 11. Graafland NM, Teertstra HJ, Besnard AP, et al. Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol 2011; 185: 881-887.
11. Graafland NM, Teertstra HJ, Besnard AP, et al. Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol 2011; 185: 881-887.
12. Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook, 7th ed. New York, NY: Springer, 2010.
13. Thuret R, Sun M, Abdollah F, et al. Tumor grade improves the prognostic ability of American Joint Committee on Cancer stage in patients with penile carcinoma. J Urol 2011; 185: 501-507.
14. Graafland NM, Lam W, Leijte JA, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol 2010; 58: 742-747.
15. Minhas S, Kayes O, Hegarty P, et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005; 96: 1040-1043.
16. Rozan R, Albuisson E, Giraud B, et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995; 36: 83-93.
17. Kiltie AE, Elwell C, Close HJ, et al. Iridium-192 implantation for node-negative carcinoma of the penis: the Cookridge Hospital experience. Clin Oncol (R Coll Radiol) 2000; 12: 25-31.
18. de Crevoisier R, Slimane K, Sanfilippo N, et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 2009; 74: 1150-1156.
19. Crook J, Grimard L, Tsihlias J, et al. Interstitial brachytherapy for penile cancer: an alternative to amputation. J Urol 2002; 167: 506-511.
20. Crook JM, Haie-Meder C, Demanes DJ, et al. American Brachytherapy Society- Groupe Europeén de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy 2013; 12: 191-198.
21. Zouhair A, Coucke PA, Jeanneret W, et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer 2001; 37: 198-203.
22. Gotsadze D, Matveev B, Zak B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol 2000; 38: 306-312.
23. Sarin R, Norman AR, Steel GG, Horwich A. Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. Int J Radiat Oncol Biol Phys 1997; 38: 713-722.
24. Opjordsmoen S, Waehre H, Aass N, Fossa SD. Sexuality in patients treated for penile cancer: patients' experience and doctors' judgement. Br J Urol 1994; 73: 554-560.
25. Horenblas S, van Tinteren H, Delemarre JF, et al. Squamous cell carcinoma of the penis. III. treatment of regional lymph nodes. J Urol 1993; 149: 492-497.
26. Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol 2003; 170: 359-365.
27. Ozsahin M, Jichlinski P, Weber DC, et al. Treatment of penile carcinoma: to cut or not to cut?. Int J Radiat Oncol Biol Phys 2006; 66: 674-679.
28. Chen MF, Chen WC, Wu CT, et al. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol 2004; 22: 60-66.
29. Pedrick TJ, Wheeler W, Riemenschneider H. Combined modality therapy for locally advanced penile squamous cell carcinoma. Am J Clin Oncol 1993; 16: 501-505.
30. Eliason M, Bowen G, Bowen A, et al. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol 2009; 145: 950-952.
31. Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161: 1823-1825.
32. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28: 3851-3857.
33. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546-551.
34. Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol 1997; 32: 5-15.
35. Leijte JA, Kerst JM, Bais E, et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007; 52: 488-494.
36. Bermejo C, Busby JE, Spiess PE, et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177: 1335-1338.
37. Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19: 1304-1307.
38. Power DG, Galvin DJ, Cuffe S, et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27: 187-190.
39. Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012; 110: E661-E666.
40. Di Lorenzo G, Federico P, Buonerba C, et al. Paclitaxel in pretreated metastatic penile cancer; final results of a phase 2 study. Eur Urol 2011; 60: 1280-1284.
41. Alnajjar HM, Lam W, Bolgeri M, et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 2012; 62: 923-928.
42. Feldman AS, McDougal WS. Long-term outcome of excisional organ sparing surgery for carcinoma of the penis. J Urol 2011; 186: 1303-1307.
43. Bandieramonte G, Colecchia M, Mariani L, et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol 2008; 54: 875-882.
44. Windahl T, Andersson SO. Combined laser treatment for penile carcinoma: results after long-term followup. J Urol 2003; 169: 2118-2121.
45. Hadway P, Corbishley CM, Watkin NA. Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int 2006; 98: 532-536.
46. Shabbir M, Muneer A, Kalsi J, et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol 2011; 59: 142-147.
47. Smith Y, Hadway P, Biedrzycki O, et al. Reconstructive surgery for invasive squamous carcinoma of the glans penis. Eur Urol 2007; 52: 1179-1185.
48. Schlenker B, Tilki D, Seitz M, et al. Organ-preserving neodymium-yttriumaluminium- garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int 2010; 106: 786-790.
49. Azrif M, Logue JP, Swindell R, et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol) 2006; 18: 320-325.
50. Crook JM, Girmard L, Esche B, Pond G. Penile brachytherapy: results for 60 patients. Brachytherapy 2007; 6: 82.
51. Lont AP, Gallee MP, Meinhardt W, et al. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol 2006; 176: 575-580; discussion 580.
52. Crook J, Jezioranski J, Cygler JE. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy 2010; 9: 151-158.
53. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Penile Cancer, version 1, 2013. http://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. (15 July 2013, date last accessed).
54. Ornellas AA, Kinchin EW, Nóbrega BL, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute longterm experience. J Surg Oncol 2008; 97: 487-495.
55. Leijte JA, Kroon BK, Valdés Olmos RA, et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol 2007; 52: 170-177.
56. Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 2006; 97: 1225-1228.
57. Graafland NM, Moonen LM, van Boven HH, et al. Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for management. J Urol 2011; 185: 888-893.
58. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76 (Suppl. 1): S58-S65.
59. Horenblas S. Lymphadenectomy in penile cancer. Urol Clin North Am 2011; 38: 459-469, vi-vii.
60. Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two- centre analysis of 700 patients. Eur Urol 2008; 54: 161-168.